A novel, non-hallucinogenic, experimental drug shows statistically significant, rapid, and durable improvement in PTSD symptom severity in a phase 2 trial.
In the DSM-5 released in May, PTSD just got more complex. It added a new symptom domain of "negative alterations in cognitions or mood," and expanded the hyperarousal domain to include aggressive, ...
MedPage Today on MSN
Novel rapid-acting drug proves effective in severe PTSD
Results support the neuroplastogen as a "potential acute, intermittent" therapy, researche ...
USA: The investigational neuroplastogen TSND-201 demonstrated significant efficacy in patients with severe post-traumatic stress disorder (PTSD) in a randomized phase II trial. A ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with functional neurological disorders or ...
High functioning PTSD often hides behind success. Here are the subtle signs you’re surviving in trauma survival mode instead of truly thriving. TheHealthSite.com ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results